{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:50:21Z","timestamp":1787611821817,"version":"build-2736575974"},"reference-count":23,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,1,11]]},"abstract":"<jats:p>\n                    A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of\n                    <jats:italic>Plasmodium vivax<\/jats:italic>\n                    malaria in patients aged \u226516 years. Recently, however, Watson et al. suggested that the approved dose of tafenoquine is insufficient for radical cure, and that a higher 450 mg dose could reduce P. vivax recurrences substantially (Watson et al., 2022). In this response, we challenge Watson et al.'s assertion based on empirical evidence from dose-ranging and pivotal studies (published) as well as real-world evidence from post-approval studies (ongoing, therefore currently unpublished). We assert that, collectively, these data confirm that the benefit\u2013risk profile of a single 300 mg dose of tafenoquine, co-administered with chloroquine, for the radical cure of\n                    <jats:italic>P. vivax<\/jats:italic>\n                    malaria in patients who are not G6PD-deficient, continues to be favourable where chloroquine is indicated for\n                    <jats:italic>P. vivax<\/jats:italic>\n                    malaria. If real-world evidence of sub-optimal efficacy in certain regions is observed or dose-optimisation with other blood-stage therapies is required, then well-designed clinical studies assessing safety and efficacy will be required before higher doses are approved for clinical use.\n                  <\/jats:p>","DOI":"10.7554\/elife.89263","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T14:15:09Z","timestamp":1704982509000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.89263","source":"Crossref","is-referenced-by-count":2,"title":["Comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'"],"prefix":"10.7554","volume":"13","author":[{"given":"Raman","family":"Sharma","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Stevenage, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Brentford, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3822-497X","authenticated-orcid":true,"given":"Lionel","family":"Tan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Brentford, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-4891","authenticated-orcid":true,"given":"Katie","family":"Rolfe","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Stevenage, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Ioana-Gabriela","family":"Fi\u0163a","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Brentford, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1649-8133","authenticated-orcid":true,"given":"Si\u00f4n","family":"Jones","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Brentford, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-7323","authenticated-orcid":true,"given":"Anup","family":"Pingle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01tvt4d48","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Mumbai, India"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1338-1290","authenticated-orcid":true,"given":"Rachel A","family":"Gibson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Stevenage, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Navin","family":"Goyal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/025vn3989","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Upper Providence, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-2344","authenticated-orcid":true,"given":"Hema","family":"Sharma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Brentford, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Panayota","family":"Bird","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xsqw823","id-type":"ROR","asserted-by":"publisher"}],"name":"GSK","place":["Brentford, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"4374","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.trsl.2014.09.009","type":"journal-article","article-title":"Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells","volume":"165","author":"Baird","year":"2015","journal-title":"Translational Research"},{"key":"bib2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00011-19","type":"journal-article","article-title":"8-aminoquinoline therapy for latent malaria","volume":"32","author":"Baird","year":"2019","journal-title":"Clinical Microbiology Reviews"},{"key":"bib3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002224","type":"journal-article","article-title":"Haemolysis in G6PD heterozygous females treated with primaquine for plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens","volume":"14","author":"Chu","year":"2017","journal-title":"PLOS Medicine"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/inthealth\/ihy060","type":"journal-article","article-title":"Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities","volume":"11","author":"Domingo","year":"2019","journal-title":"International Health"},{"key":"bib5","type":"web-resource","article-title":"US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria","author":"GSK","year":"2018","unstructured":"GSK. 2018a. US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria\/ [Accessed April 26, 2023]."},{"key":"bib6","type":"web-resource","article-title":"Krintafel. Highlights of prescribing information","author":"GSK","year":"2018","unstructured":"GSK. 2018b. Krintafel. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210795s000lbl.pdf [Accessed April 26, 2023]."},{"key":"bib7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/IDR.S151031","type":"journal-article","article-title":"Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data","volume":"12","author":"Hounkpatin","year":"2019","journal-title":"Infection and Drug Resistance"},{"key":"bib8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339","type":"journal-article","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map","volume":"9","author":"Howes","year":"2012","journal-title":"PLOS Medicine"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","type":"journal-article","article-title":"Single-dose tafenoquine to prevent relapse of plasmodium vivax malaria","volume":"380","author":"Lacerda","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","type":"journal-article","article-title":"Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study","volume":"383","author":"Llanos-Cuentas","year":"2014","journal-title":"Lancet"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","type":"journal-article","article-title":"Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria","volume":"380","author":"Llanos-Cuentas","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"bib12","type":"web-resource","article-title":"Press release: Tafenoquine approved in Peru","author":"Medicines for Malaria Venture","year":"2021","unstructured":"Medicines for Malaria Venture. 2021. Press release: Tafenoquine approved in Peru. https:\/\/www.vivaxmalaria.org\/sites\/pvivax\/files\/content\/attachments\/2021-01-25\/GSK%20-%20MMV%20PRESS%20RELEASE%20TAFENOQUINE%20APPROVED%20IN%20PERU.pdf [Accessed April 26, 2023]."},{"key":"bib13","type":"web-resource","article-title":"Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration","author":"Medicines for Malaria Venture","year":"2022","unstructured":"Medicines for Malaria Venture. 2022. Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration. https:\/\/www.mmv.org\/newsroom\/press-releases\/single-dose-kozenis-tafenoquine-approved-children-plasmodium-vivax-malaria [Accessed April 26, 2023]."},{"key":"bib14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012656.pub2","type":"journal-article","article-title":"Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria","volume":"7","author":"Milligan","year":"2019","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"bib15","type":"web-resource","article-title":"G6PD global prevalence","author":"P. vivax information hub","year":"2012","unstructured":"P. vivax information hub. 2012. G6PD global prevalence. https:\/\/www.vivaxmalaria.org\/diagnosis-treatment\/g6pd-deficiency\/g6pd-global-prevalence#:~:text=G6PD%20Global%20Prevalence,-Photo%3A%20Jaya%20Banerji&text=G6PD%20deficiency%20affects%20around%20400%20million%20people%20globally [Accessed April 26, 2023]."},{"key":"bib16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.4269\/ajtmh.16-0779","type":"journal-article","article-title":"Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers","volume":"97","author":"Rueangweerayut","year":"2017","journal-title":"The American Journal of Tropical Medicine and Hygiene"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.4269\/ajtmh.22-0387","type":"journal-article","article-title":"Historical 8-aminoquinoline combinations: not all antimalarial drugs work well together","volume":"107","author":"Shanks","year":"2022","journal-title":"The American Journal of Tropical Medicine and Hygiene"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(23)00213-X","type":"journal-article","article-title":"Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study","volume":"23","author":"Sutanto","year":"2023","journal-title":"The Lancet Infectious Diseases"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1128\/AAC.00718-15","type":"journal-article","article-title":"Exposure-response analyses for tafenoquine after administration to patients with plasmodium vivax malaria","volume":"59","author":"Tenero","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S2352-4642(21)00328-X","type":"journal-article","article-title":"Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial","volume":"6","author":"V\u00e9lez","year":"2022","journal-title":"The Lancet. Child & Adolescent Health"},{"key":"bib21","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83433","type":"journal-article","article-title":"The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis","volume":"11","author":"Watson","year":"2022","journal-title":"eLife"},{"key":"bib22","type":"web-resource","article-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Guidelines for the treatment of malaria. https:\/\/apps.who.int\/iris\/handle\/10665\/162441 [Accessed April 26, 2023]."},{"key":"bib23","type":"web-resource","article-title":"Global Malaria Programme","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. 2023. Global Malaria Programme. https:\/\/www.who.int\/teams\/global-malaria-programme [Accessed April 26, 2023]."}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/89263\/elife-89263-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/89263\/elife-89263-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/89263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:41:56Z","timestamp":1787568116000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/89263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":23,"alternative-id":["10.7554\/eLife.89263"],"URL":"https:\/\/doi.org\/10.7554\/elife.89263","archive":["CLOCKSS"],"relation":{"has-review":[{"id-type":"doi","id":"10.7554\/eLife.89263.sa2","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.89263.sa1","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"article-number":"e89263"}}